New U.S. DOT Guidance on Marijuana and Drug Testing – What It Likely Means for Canada
The U.S. Department of Transportation (DOT) has just released new guidance clarifying how Medical Review Officers (MROs) must handle marijuana-positive drug tests, even in light of changing cannabis laws and the recent rescheduling announcement by the U.S. Drug Enforcement Administration (DEA).
Because Canadian transportation and occupational health guidance often evolves to stay broadly aligned with U.S. federal standards—especially in cross-border and safety-sensitive sectors—it is very likely that Canadian expectations will track closely with this stance over time.
For employers in safety-sensitive industries in Canada (transport, construction, oil and gas, mining, etc.), this is an important signal: legalization, medical authorization, or rescheduling of cannabis does not automatically translate into an acceptable or excusable safety risk in the workplace.
What Changed in the U.S.: DEA Rescheduling and DOT Response
In the U.S., the DEA recently issued an order reclassifying certain FDA-approved drug products derived from marijuana, and some marijuana products regulated under state medical programs, from Schedule I to Schedule III under the Controlled Substances Act (CSA).
At first glance, this might sound like marijuana is becoming more acceptable or “less serious” from a regulatory standpoint. However, the DOT has made it clear that this rescheduling does not change how workplace drug tests for marijuana must be interpreted for federally regulated, safety-sensitive employees.
The Key Question: Can an MRO Change a Marijuana Positive to Negative?
The DOT directly addressed the central question many employers and employees are asking:
When reviewing a lab-reported marijuana positive drug test result, can a Medical Review Officer deem the test “negative” if the employee says the result came from using a state‑licensed marijuana product?
The DOT’s answer is unequivocal: No.
There is currently no situation in which an MRO can verify a laboratory-confirmed marijuana positive result as negative simply because an employee claims they used a state-licensed or medically authorized marijuana product.
Why Not? “Legitimate Medical Explanation” Has a Very Specific Meaning
Under DOT rules, an MRO can change a positive result to negative only if there is a legitimate medical explanation under federal law.
DOT emphasizes several crucial points:
Even after rescheduling, state-dispensed marijuana is not an FDA‑approved drug.
Without FDA approval, a controlled substance cannot be prescribed under U.S. federal law in the way other medications can.
A “legitimate medical explanation” requires the use of a legally prescribed controlled substance that complies with federal laws, not just state laws. This is reflected in U.S. regulations 49 CFR §§ 40.137(a) and 40.141(b).
This is a critical distinction: state-level programs, cards, or recommendations do not override federal safety requirements in regulated transportation testing programs.
Medical Marijuana Cards and Dispensary Records Don’t Qualify
The DOT also clarifies what does not count as a legitimate medical explanation under its drug testing rules. Even if an employee produces:
A state-issued medical marijuana card
A physician’s recommendation or certification for cannabis
Dispensary records, purchase receipts, or similar documents
these do not satisfy the requirements in Part 40 for a legitimate medical explanation for a marijuana-positive drug test.
In other words, documentation tied to a state medical marijuana program or a non-prescription source is not enough to overturn a marijuana-positive result in the DOT-regulated context.
Marijuana and Safety-Sensitive Work: Incompatible by Design
The DOT guidance finishes with a clear safety message: marijuana use is not compatible with safety-sensitive functions.
Safety-sensitive roles include those where impairment can have catastrophic consequences—such as operating commercial vehicles, heavy equipment, working at heights, or managing critical systems.
Even in a world where recreational or medical cannabis is legal under some laws, regulators continue to treat cannabis use as fundamentally inconsistent with the requirements of safety-sensitive work.
What This Likely Signals for Canadian Employers
While this is a U.S. development, it sends a strong signal for Canadian organizations, especially those:
Operating cross-border transportation or logistics
Subject to U.S. DOT regulations for certain workers
Managing high-risk, safety-sensitive environments
Canadian federal and provincial regulators have consistently emphasized that legalization of cannabis does not give employees the right to be impaired at work, especially in safety-sensitive roles.
This new DOT guidance reinforces a few practical principles that are very likely to align with current and future Canadian expectations:
A positive test for THC will still be treated as a serious safety concern, regardless of whether use is recreational or medical.
“Medical cannabis” authorization or proof of purchase is unlikely to be accepted as a full defence for a positive result in a safety-sensitive context.
Employers remain responsible for ensuring workers in safety-sensitive roles are not impaired and can safely perform their duties.
For Canadian companies, the safest approach is to assume that regulators, arbitrators, and courts will continue to view cannabis differently from standard prescription medications when it comes to safety-sensitive work.
What Employers Can Do Now
Canadian employers may want to:
Review and update their fit-for-duty and drug and alcohol policies to be explicit about cannabis and safety-sensitive roles
Clarify expectations around disclosure of medications and how potential impairment will be managed
Provide training to supervisors and employees on cannabis, impairment, and safety obligations
Seek occupational health or legal advice when accommodating medical cannabis while protecting safety
Prairie Industrial Health Services can help organizations in Saskatoon and beyond interpret these developments, review policies, and align occupational testing programs with best practices that reflect both Canadian law and U.S. trends.
To make this most useful for you, what kind of audience are you targeting with this blog post (for example, HR professionals, safety managers, or general employees), so the tone and examples can be adjusted to match them?